Magnum’s Sugar Rush Ends as GLP-1 Fears Return

Core Insights - Magnum Ice Cream Company's first results post-demerger from Unilever revealed disappointing performance, with a 3% decline in fourth quarter sales volumes and a nearly 50% drop in annual profit, raising concerns about the viability of indulgent ice cream in the current market [1][2][6]. Financial Performance - Fourth quarter sales volumes decreased by 3%, contrary to expectations for slight growth, while full-year revenue remained flat at €7.9 billion ($9.4 billion), with organic sales increasing by 4.2% due to 2.6% pricing and 1.5% volume growth overall [2]. - Operating profit fell from €764 million to €599 million, and net profit dropped by 48% to €307 million, impacted by separation and restructuring costs [3]. - Free cash flow decreased significantly to €38 million from €803 million the previous year, reflecting demerger outflows and new financing [3]. - Net debt rose to nearly €3 billion, and the adjusted EBITDA margin declined to 15.9% from 16.9% in 2024 [3]. Market Reaction - Following the disappointing results, shares of Magnum, which had previously risen by 25% to 30% since listing, fell by as much as 15% to 16% in Amsterdam [4]. Strategic Considerations - The rationale behind the spin-off was to create a focused ice cream company capable of driving faster growth and sharper execution, but the current performance raises questions about whether indulgent ice cream is facing structural challenges [6]. - The emergence of GLP-1 weight-loss drugs is causing investors to reassess high-calorie categories, as these appetite-suppressing treatments may lead consumers to reduce their consumption of premium ice cream products [7]. - Despite the fourth quarter volume decline, management suggests that this does not indicate a structural shift, citing commodity inflation, currency headwinds, and operational challenges from the separation as contributing factors [8].